AU5956001A - Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists - Google Patents

Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists

Info

Publication number
AU5956001A
AU5956001A AU5956001A AU5956001A AU5956001A AU 5956001 A AU5956001 A AU 5956001A AU 5956001 A AU5956001 A AU 5956001A AU 5956001 A AU5956001 A AU 5956001A AU 5956001 A AU5956001 A AU 5956001A
Authority
AU
Australia
Prior art keywords
methods
side effects
adverse side
novel compositions
opioid agonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU5956001A
Inventor
Barry Sherman
Mary Remien
Remi Barbier
Kathleen Dumas
Grant Schoenhard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Albert Einstein College of Medicine
Pain Therapeutics Inc
Original Assignee
Albert Einstein College of Medicine
Pain Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US20226800P priority Critical
Priority to US56607100A priority
Priority to US20222700P priority
Priority to PCT/US2000/012493 priority patent/WO2000067739A2/en
Priority to US24448200P priority
Priority to US24511000P priority
Priority to US24623500P priority
Priority to US75633101A priority
Application filed by Albert Einstein College of Medicine, Pain Therapeutics Inc filed Critical Albert Einstein College of Medicine
Priority to PCT/US2001/014644 priority patent/WO2001085150A2/en
Publication of AU5956001A publication Critical patent/AU5956001A/en
Application status is Pending legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
AU5956001A 1999-05-06 2001-05-04 Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists Pending AU5956001A (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
US20226800P true 2000-05-05 2000-05-05
US56607100A true 2000-05-05 2000-05-05
US20222700P true 2000-05-05 2000-05-05
PCT/US2000/012493 WO2000067739A2 (en) 1999-05-06 2000-05-05 Opioid antagonists containing compositions for enhancing analgesic potency of tramadol and attenuating its adverse side effects
US24448200P true 2000-10-30 2000-10-30
US24511000P true 2000-11-01 2000-11-01
US24623500P true 2000-11-02 2000-11-02
US75633101A true 2001-01-08 2001-01-08
PCT/US2001/014644 WO2001085150A2 (en) 2000-05-05 2001-05-04 Opioid antagonist containing composition for enchaching the potency or reducing adverse side effects ofopioid agonists

Publications (1)

Publication Number Publication Date
AU5956001A true AU5956001A (en) 2001-11-20

Family

ID=27573954

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2001259560A Ceased AU2001259560B2 (en) 1999-05-06 2001-05-04 Opioid antagonist containing composition for enhancing the potency or reducing adverse side effects of opioid agonists
AU2001259458A Ceased AU2001259458B2 (en) 1999-05-06 2001-05-04 Opioid antagonist compositions and dosage forms
AU5956001A Pending AU5956001A (en) 1999-05-06 2001-05-04 Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AU2001259560A Ceased AU2001259560B2 (en) 1999-05-06 2001-05-04 Opioid antagonist containing composition for enhancing the potency or reducing adverse side effects of opioid agonists
AU2001259458A Ceased AU2001259458B2 (en) 1999-05-06 2001-05-04 Opioid antagonist compositions and dosage forms

Country Status (5)

Country Link
EP (1) EP1280529A2 (en)
JP (1) JP2004501094A (en)
AU (3) AU2001259560B2 (en)
CA (1) CA2408098A1 (en)
WO (1) WO2001085150A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2266564T3 (en) 1997-12-22 2013-06-03 Euro Celtique Sa A pharmaceutical oral dosage form comprising a combination of an opioid agonist and an opioid antagonist
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
AR031682A1 (en) * 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk pharmaceutical compositions
EP1392265A2 (en) * 2000-10-30 2004-03-03 Pain Therapeutics, Inc. Inhibitors of abc drug transporters at the blood-brain barrier
CA2446550C (en) 2001-05-11 2012-03-06 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
TWI334779B (en) 2002-04-05 2010-12-21 Euro Celtique Sa Pharmaceutical preparation containing oxycodone and naloxone
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
EP1680143A2 (en) * 2003-10-15 2006-07-19 Pain Therapeutics, Inc. Treatment of arthritic conditions, chronic inflammation or pain
US20050245557A1 (en) * 2003-10-15 2005-11-03 Pain Therapeutics, Inc. Methods and materials useful for the treatment of arthritic conditions, inflammation associated with a chronic condition or chronic pain
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
CA2609733C (en) * 2005-05-25 2011-07-19 Shionogi & Co., Ltd. 6,7-unsaturated-7-carbamoyl-substituted morphinan derivative
WO2006126529A1 (en) 2005-05-25 2006-11-30 Shionogi & Co., Ltd. 6,7-unsaturated-7-carbamoyl substituted morphinan derivative
JP2011511782A (en) * 2008-02-12 2011-04-14 アボット・ラボラトリーズAbbott Laboratories Extended release hydrocodone acetaminophen and its related methods and applications
WO2010103039A1 (en) 2009-03-10 2010-09-16 Euro-Celtique S.A. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
ES2703623T3 (en) * 2013-06-28 2019-03-11 Purdue Pharma Lp Opioid antagonists for use in the treatment of arrhythmia induced by opioid analgesics
JP2016525138A (en) 2013-07-23 2016-08-22 ユーロ−セルティーク エス.エイ. The combination of oxycodone and naloxone for use in the treatment of pain in patients suffering from diseases increase the risk for diseases and / or Enterobacteriaceae migration results in pain and intestinal Disconnect bio cis
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CA2955229A1 (en) 2014-07-17 2016-01-21 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5512578A (en) * 1992-09-21 1996-04-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US6103258A (en) * 1996-04-12 2000-08-15 Simon; David Lew Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics
DK2266564T3 (en) * 1997-12-22 2013-06-03 Euro Celtique Sa A pharmaceutical oral dosage form comprising a combination of an opioid agonist and an opioid antagonist
CA2314896C (en) * 1997-12-22 2005-09-13 Euro-Celtique, S.A. A method of preventing abuse of opioid dosage forms

Also Published As

Publication number Publication date
WO2001085150A3 (en) 2002-08-08
WO2001085150A2 (en) 2001-11-15
AU2001259560B2 (en) 2007-02-15
AU2001259458B2 (en) 2006-09-14
JP2004501094A (en) 2004-01-15
CA2408098A1 (en) 2001-11-15
EP1280529A2 (en) 2003-02-05

Similar Documents

Publication Publication Date Title
TWI292399B (en) Pharmaceutical compositions and combinations of novel non-imidazole compounds
DE60039711D1 (en) Hydromorphinone and hydrocodeinone compositions and methods for their synthesis
GB2353523B (en) Methods and compositions for use in cementing in cold environments
HU0102272D0 (en) Compositions and methods for stimulating gastrointestinal motilis
HU0400641A3 (en) Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
HU0401819A3 (en) Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
HU0101804A3 (en) Adjuvant composition and methods for its use
AU7292501A (en) Use of interleukin-4 antagonists and compositions thereof
HK1061851A1 (en) Gyrase inhibitors and uses thereof
HK1064284A1 (en) Antibody inhibitors of gdf-8 and uses thereof gdf-8
IL164987D0 (en) Proline derivatives and pharmaceutical compositions containing
AU6118001A (en) Combination therapeutic compositions and methods of use
IL152022A (en) Compounds useful as protease inhibitors and pharmaceutical compositions containing the same
SI1274728T1 (en) Methods and compositions for the prevention and treatment of anemia
PL357931A1 (en) Brightening compositions for local application and method of using them
GB0018828D0 (en) Alkyl Amino Acid Derivatives useful as pharmaceutical agents
GB0022635D0 (en) Compositions and methods for cementing using elastic particles
ZA200207956B (en) 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors.
AU4543701A (en) Lightweight methods and compositions for well treating
IL213594D0 (en) Uses of pharmaceutical compositions comprising an alkaoid3
AU8911801A (en) Improved nanocomposite compositions and methods for making and using same
AU2001249072A1 (en) Lipase-containing composition and methods of use thereof
AU4996701A (en) Composition and methods for tissue preservation
IL156737D0 (en) Substituted amine derivatives and methods of use
IL180523D0 (en) Compositions for iapp-inhibition and uses thereon